Tag: NASDAQ:GILD

BioTech

Biotech Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Inovio Pharmaceuticals Inc (NYSEMKT:INO), Geron Corporation (NASDAQ:GERN)

The iShares Biotechnology Indexhas fallen 2.46% in the last month of trading, and biotech stalwarts Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD ) are both down over 8%. What’s most surprising is that Celgene and Gilead are expected to have strong years in terms of earnings and the development of their respective clinical pipelines. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 0.53% in last session and … Continue reading Biotech Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Inovio Pharmaceuticals Inc (NYSEMKT:INO), Geron Corporation (NASDAQ:GERN)

Mark DeFrance
BioTech

Biotech Most Active Stocks: Geron Corporation (NASDAQ:GERN), Pfizer Inc. (NYSE:PFE), OXiGENE Inc (NASDAQ:OXGN), Gilead Sciences (NASDAQ:GILD)

Geron Corporation (NASDAQ:GERN)  got bad news about its key imetelstat drug, as the FDA issued a clinical hold on the treatment for multiple myeloma and essential thrombocythemia. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the average volume of the stock remained 4.64 million shares. The … Continue reading Biotech Most Active Stocks: Geron Corporation (NASDAQ:GERN), Pfizer Inc. (NYSE:PFE), OXiGENE Inc (NASDAQ:OXGN), Gilead Sciences (NASDAQ:GILD)

Kevin Long
BioTech

Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Kristen Barton
BioTech

Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD), CEL-SCI (NYSEMKT:CVM), Inovio Pharmaceuticals (NYSEMKT:INO)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares declined 1.14% to $8.65. The company on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -2.87% in last session and finished the day at $8.13. Traded volume was 13.50million shares in the last session and the average volume … Continue reading Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD), CEL-SCI (NYSEMKT:CVM), Inovio Pharmaceuticals (NYSEMKT:INO)

Jason Knox
BioTech

Healthcare Active runners: Zogenix (NASDAQ:ZGNX), Boston Scientific (NYSE:BSX), Galena Biopharma (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD)

Officials with Zogenix Inc. (NASDAQ:ZGNX), the San Diego-based maker of Zohydro, did not return a message seeking comment about the drug. The company is marketing the drug as the first extended-release hydrocodone pain reliever without acetaminophen, which can cause liver failure if taken in excess. Zogenix, Inc. (NASDAQ:ZGNX) stock performance was -14.18% in last session and finished the day at $3.84. Traded volume was 9.38million … Continue reading Healthcare Active runners: Zogenix (NASDAQ:ZGNX), Boston Scientific (NYSE:BSX), Galena Biopharma (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD)

Kristen Barton
FB Nasdaq FB Facebook
Analyst Actions

Gilead (NASDAQ:GILD) Altripla Recall a Non-Issue According to Deutsche Bank

Deutsche Bank said Gilead(NASDAQ:GILD)’s Atripla recall is not an issue. The firm said Gilead proactively issued the recall following a typical quality check that found small particles and notes the company has multiple manufacturers for Atripla. Management said it was a minor issue and that Atripla supply is more than enough. Shares are Buy rated with a $132 price target. In a note issued by … Continue reading Gilead (NASDAQ:GILD) Altripla Recall a Non-Issue According to Deutsche Bank

John Meady